Friday, 17 Aug 2018

You are here

Zilretta - a New Drug FDA Approved for Osteoarthritis of the Knee

Flexion Therapeutics announced friday that the U.S. Food and Drug Administration (FDA) has approved its osteoarthritis (OA) of the knee injectable steroid drug Zilretta with the indication of moderate-to-severe knee pain.

Zilretta is the commonly used triamcinolon acetonide combined with a drug delivery system designed to provide extended pain relief over three months.

It will be priced at $570 per dose. The company claims the therapy to be cost effective based on a comparative analysis against diclofenac or hyaluronic acid (HA) injections presented earlier this year.   

They claim that Zilretta produced an average QALY gain from baseline of 0.189 per six months, which suggests a greater improvement in quality of life compared with the average values for conventional care (0.030), diclofenac (0.078) and HA injections (0.109). Zilretta yielded a cost per QALY estimate of $3,201, compared with cost per QALY estimates for conventional care ($10,717), diclofenac ($2,708) and an average HA treatment course ($13,389). (Citation source: https://buff.ly/2fW2CgE)

In a nearly 500-patient Phase 3 study, Zilretta significantly lowered pain intensity scores compared to placebo three months following administration. A secondary analysis comparing Zilretta to an active control of immediate-release triamcinolone acetonide showed numerically superior reduction but failed to hit statistical significance. 

Flexion, though, is also touting Zilretta's muted effect on blood sugar levels. Spikes in blood glucose levels are a known potential side effect of corticosteroids. Roughly one-fifth of OA patients have type 2 diabetes, meaning a pain treatment with a reduced risk of increasing blood sugar would likely be viewed more favorably by physicians. 

 A small study of Zilretta with type 2 diabetes patients showed treatment with the drug led to a significantly smaller increase in blood glucose levels than other formulations of triamcinolone acetonide. 

The market for osteoarthritis drugs is expected to increase from $1.6 billion in 2016 to $3.5 billion by 2026, according to GlobalData.

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Persistent Osteoporosis Drug Use Pays Off

Among elderly female Medicare patients, persistent use of osteoporosis medications was associated with reduced risk of fracture and significantly lower total health care costs.

Osteoporosis International reports the results of research examining records of 294,369 women >65 years old, on Medicare and taking osteoporosis medicines for the first time at some point between 2009 and 2011. (Citation Source: bit.ly/2vALm98) 

Fractures Augment 10 Year Mortality Risks

This nationwide study of adults (50+ yrs) from Denmark has shown that following a fragility fracture, the 10-years mortality risk was increased, especially in the first year following the fracture. 

Early Hip Fracture Surgery Reduces Mortality

CMAJ reports that seniors are more likely to survive a hip fracture if the surgery is done as soon as they’re admitted to the hospital - suggesting hospitals should expedite operating room access for patients whose surgery has already been delayed for nonmedical reasons. (Citation source: bit.ly/2KzdrCt) 

Big Advances for Two Osteoporosis Drugs

New developments with the FDA and new scientific findings are adding momentum to two drugs experts believe are game-changers in osteoporosis treatment.

In May, the FDA approved denosumab (Prolia) for use in patients who have glucocorticoid-induced osteoporosis and are at high risk of fracture. 

Update on Osteoporosis

This session was an update on the management of osteoporosis given by Professor Christian Roux from France.

He emphasised the use of composite risk score like the FRAX. He highlighted that the risk of vertebral fracture is increased by both the recency and severity of previous vertebral fracture. So it is important that those with vertebral fractures are followed up and treated appropriately to prevent subsequent fractures.